Business Description
China SXT Pharmaceuticals Inc
ISIN : VGG2161P1403
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.56 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -1.13 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -1.39 | |||||
Beneish M-Score | -2.78 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -76.2 | |||||
3-Year EBITDA Growth Rate | 65.1 | |||||
3-Year EPS without NRI Growth Rate | 66.6 | |||||
3-Year FCF Growth Rate | 64.2 | |||||
3-Year Book Growth Rate | -77 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.27 | |||||
9-Day RSI | 43.89 | |||||
14-Day RSI | 43.15 | |||||
3-1 Month Momentum % | -25.54 | |||||
6-1 Month Momentum % | -57.25 | |||||
12-1 Month Momentum % | -75.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.51 | |||||
Cash Ratio | 1.36 | |||||
Days Inventory | 160.95 | |||||
Days Sales Outstanding | 250.46 | |||||
Days Payable | 351.64 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -314.9 | |||||
Shareholder Yield % | -25.52 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 28.72 | |||||
Operating Margin % | -130.38 | |||||
Net Margin % | -160.6 | |||||
FCF Margin % | -99.55 | |||||
ROE % | -27.58 | |||||
ROA % | -13.82 | |||||
ROIC % | -23.77 | |||||
3-Year ROIIC % | 51.81 | |||||
ROC (Joel Greenblatt) % | -264.04 | |||||
ROCE % | -22.11 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.15 | |||||
PB Ratio | 0.06 | |||||
Price-to-Tangible-Book | 0.06 | |||||
EV-to-EBIT | 3.09 | |||||
EV-to-EBITDA | 3.35 | |||||
EV-to-Revenue | -4.09 | |||||
EV-to-FCF | 4.04 | |||||
Price-to-GF-Value | 0.37 | |||||
Price-to-Projected-FCF | 0.04 | |||||
Price-to-Net-Current-Asset-Value | 0.17 | |||||
Price-to-Net-Cash | 0.29 | |||||
Earnings Yield (Greenblatt) % | 32.38 | |||||
FCF Yield % | -122.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
China SXT Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.791 | ||
EPS (TTM) (€) | -15.386 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | 69.95 | ||
14-Day RSI | 43.15 | ||
14-Day ATR (€) | 0.030446 | ||
20-Day SMA (€) | 0.367125 | ||
12-1 Month Momentum % | -75.41 | ||
52-Week Range (€) | 0.3275 - 3.4 | ||
Shares Outstanding (Mil) | 4.06 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
China SXT Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
China SXT Pharmaceuticals Inc Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
China SXT Pharmaceuticals Inc Frequently Asked Questions
What is China SXT Pharmaceuticals Inc(STU:2RY0)'s stock price today?
When is next earnings date of China SXT Pharmaceuticals Inc(STU:2RY0)?
Does China SXT Pharmaceuticals Inc(STU:2RY0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |